180 related articles for article (PubMed ID: 11417749)
1. Angiogenic and immune parameters during recombinant interferon-alpha2b adjuvant treatment in patients with melanoma.
Dréau D; Foster M; Hogg M; Swiggett J; Holder WD; White RL
Oncol Res; 2000; 12(5):241-51. PubMed ID: 11417749
[TBL] [Abstract][Full Text] [Related]
2. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival.
Ugurel S; Rappl G; Tilgen W; Reinhold U
J Clin Oncol; 2001 Jan; 19(2):577-83. PubMed ID: 11208853
[TBL] [Abstract][Full Text] [Related]
3. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b.
Yurkovetsky ZR; Kirkwood JM; Edington HD; Marrangoni AM; Velikokhatnaya L; Winans MT; Gorelik E; Lokshin AE
Clin Cancer Res; 2007 Apr; 13(8):2422-8. PubMed ID: 17438101
[TBL] [Abstract][Full Text] [Related]
4. Systemic immune changes associated with adjuvant interferon-α2b-therapy in stage III melanoma patients: failure at the effector phase?
Chevolet I; Schreuer M; Speeckaert R; Neyns B; Hoorens I; van Geel N; Krüse V; Hennart B; Allorge D; Van Gele M; Brochez L
Melanoma Res; 2015 Aug; 25(4):357-61. PubMed ID: 26050145
[TBL] [Abstract][Full Text] [Related]
5. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis.
Kleeberg UR; Suciu S; Bröcker EB; Ruiter DJ; Chartier C; Liénard D; Marsden J; Schadendorf D; Eggermont AM;
Eur J Cancer; 2004 Feb; 40(3):390-402. PubMed ID: 14746858
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma.
Sezer O; Jakob C; Eucker J; Niemöller K; Gatz F; Wernecke K; Possinger K
Eur J Haematol; 2001 Feb; 66(2):83-8. PubMed ID: 11168514
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of high-dose interferon-alpha2b adjuvant therapy for high-risk resected cutaneous melanoma.
Muggiano A; Mulas C; Fiori B; Liciardi G; Pintus M; Tanca L; Tedde A; Turno R; Desogus A
Melanoma Res; 2004 Apr; 14(2):S1-7. PubMed ID: 15057049
[TBL] [Abstract][Full Text] [Related]
8. Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment.
Ascierto PA; Napolitano M; Celentano E; Simeone E; Gentilcore G; Daponte A; Capone M; Caracò C; Calemma R; Beneduce G; Cerrone M; De Rosa V; Palmieri G; Castello G; Kirkwood JM; Marincola FM; Mozzillo N
J Transl Med; 2010 Aug; 8():76. PubMed ID: 20712892
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort study.
Li T; Jia DD; Teng LS
Invest New Drugs; 2020 Oct; 38(5):1334-1341. PubMed ID: 32072356
[TBL] [Abstract][Full Text] [Related]
10. Low-dose adjuvant interferon for stage III malignant melanoma.
Inman JL; Russell GB; Savage P; Levine EA
Am Surg; 2003 Feb; 69(2):127-30. PubMed ID: 12641352
[TBL] [Abstract][Full Text] [Related]
11. Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma.
Brennecke S; Deichmann M; Naeher H; Kurzen H
Melanoma Res; 2005 Dec; 15(6):515-22. PubMed ID: 16314737
[TBL] [Abstract][Full Text] [Related]
12. An update on pegylated IFN-α2b for the adjuvant treatment of melanoma.
Agarwala SS
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1449-59. PubMed ID: 23249109
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma.
Varker KA; Biber JE; Kefauver C; Jensen R; Lehman A; Young D; Wu H; Lesinski GB; Kendra K; Chen HX; Walker MJ; Carson WE
Ann Surg Oncol; 2007 Aug; 14(8):2367-76. PubMed ID: 17534686
[TBL] [Abstract][Full Text] [Related]
14. Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents.
Moschos SJ; Odoux C; Land SR; Agarwala S; Friedland D; Volker KM; Sidor C; Wong M; Kirkwood JM
Melanoma Res; 2007 Jun; 17(3):193-200. PubMed ID: 17505265
[TBL] [Abstract][Full Text] [Related]
15. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
[TBL] [Abstract][Full Text] [Related]
16. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.
Bouwhuis MG; Suciu S; Collette S; Aamdal S; Kruit WH; Bastholt L; Stierner U; Salès F; Patel P; Punt CJ; Hernberg M; Spatz A; ten Hagen TL; Hansson J; Eggermont AM;
J Natl Cancer Inst; 2009 Jun; 101(12):869-77. PubMed ID: 19509353
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma.
Yamazaki N; Uhara H; Wada H; Matsuda K; Yamamoto K; Shimamoto T; Kiyohara Y
J Dermatol; 2016 Oct; 43(10):1146-1153. PubMed ID: 27087489
[TBL] [Abstract][Full Text] [Related]
18. Levels of angiogenic peptides in sera from patients with carcinoid tumours during alpha-interferon treatment.
Nilsson A; Janson ET; Eriksson B; Larsson A
Anticancer Res; 2001; 21(6A):4087-90. PubMed ID: 11911297
[TBL] [Abstract][Full Text] [Related]
19. Regulatory T cells and other lymphocyte subpopulations in patients with melanoma developing interferon-induced thyroiditis during high-dose interferon-α2b treatment.
Soldevila B; Alonso N; Martínez-Arconada MJ; Granada ML; Boada A; Vallejos V; Fraile M; Fernández-Sanmartín MA; Pujol-Borrell R; Puig-Domingo M; Sanmartí A; Martínez-Cáceres EM
Clin Endocrinol (Oxf); 2013 Apr; 78(4):621-8. PubMed ID: 22957689
[TBL] [Abstract][Full Text] [Related]
20. Serum basic fibroblast growth factor and vascular endothelial growth factor in metastatic renal cell carcinoma treated with interferon alfa-2b.
Vermeulen PB; Dirix LY; Martin M; Lemmens J; Van Oosterom AT
J Natl Cancer Inst; 1997 Sep; 89(17):1316-7. PubMed ID: 9293925
[No Abstract] [Full Text] [Related]
[Next] [New Search]
